Novartis New Products – download



Benefitting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines with more than 200 projects in clinical development.

Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development.

For a detailed review of selected projects in confirmatory development, download the complete Novartis Pipeline (PDF 0.1 MB), as of December 31, 2016.

Planned Filings

New Molecule

New Indication

New Formulation




Potential Indication/Disease Area

CTL019 a Pediatric/young adult acute lymphoblastic leukemia

ACZ885 Secondary prevention of cardiovascular events

CTL019 Diffuse large B-cell lymphoma

FTY720 Pediatric multiple sclerosis

Promacta®/Revolade® Severe aplastic anemia 1st line

Tafinlar® + Mekinist® BRAF V600+ melanoma (adjuvant)

Tasigna®b Chronic myeloid leukemia treatment free remission

Signifor® Long-acting release c Cushing’s disease

GP2013b (rituximab)
Follicular lymphoma, Diffuse large B-cell lymphoma and others
(same as originator)

GP2017c (adalimumab)
Arthritides, plaque psoriasis and others
(same as originator)

LA-EP2006 (pegfilgrastim)
Chemotherapy-induced neutropenia and others
(same as originator)

Continue at:

The text above is owned by the site bellow referred.

Here is only a small part of the article, for more please follow the link

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s